FDA to review broader access to restricted peptides in July FDA to Remove 12 Popular Peptides from the Category 2 Do Not Compound List Frier Levitt FDA Peptide Update 2026: Removal from Do Not Compound List and What It Means for Pharmacies RFK Jr. & claimed regenerative peptides like BPC 157 The Niche BPC 157 FDA Approval Status 2026: RFK Jr, Advisory Committee & Reclassification FDA Peptide Reclassification 2026: What Researchers Want BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with